Microbot Medical Inc. has announced a significant advancement in its global intellectual property strategy with the granting of a new patent in China by the China National Intellectual Property Administration (CNIPA). This patent covers the robotic manipulation of a surgical tool handle, further bolstering the company's IP portfolio. This development is a key component of Microbot Medical's plan to expand its global commercialization strategy for its LIBERTY Endovascular Robotic System, which is pending FDA clearance and anticipated for a Q3 2025 launch in the U.S.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469988-en) on June 17, 2025, and is solely responsible for the information contained therein.